Metabolic glutamate receptor 5 (mGluR5) is associated with tau pathology in mild Alzheimer's disease

Yan Wang, Fang Xie, Yihui GuanAlzheimer 2024 · DOI

TL;DR

This study reveals a significant link between reduced availability of the mGluR5 receptor and increased tau pathology in the hippocampus of individuals with mild Alzheimer's disease (AD). These findings suggest that mGluR5 dysfunction may play a crucial role in early AD cognitive decline and tau spread, opening avenues for potential therapeutic interventions targeting this receptor.

What Problem Does This Paper Address?

Alzheimer's disease (AD) is a devastating neurodegenerative disorder characterized by the accumulation of amyloid plaques and tau tangles, leading to progressive cognitive impairment. While the exact mechanisms driving AD pathogenesis are still being unraveled, evidence points to synaptic dysfunction as an early event. Metabotropic glutamate receptor 5 (mGluR5), a G protein-coupled receptor involved in synaptic plasticity, is a potential therapeutic target. However, its precise relationship with the core neuropathological hallmarks of AD, particularly tau pathology in the early stages, remains underexplored. This paper aims to clarify the association between mGluR5 availability and tau deposition in mild AD, and how these factors relate to cognitive function.

Methods

The researchers conducted a single-center, cross-sectional study involving 15 patients with mild AD and 13 age-matched healthy controls (CN). They utilized Positron Emission Tomography (PET) imaging with specific radiotracers:

  • [18F] PSS232: To measure mGluR5 availability.
  • [18F] florbetapir: To assess β-amyloid deposition (though results for this tracer are not detailed in the provided text).
  • [18F] MK6240: To quantify tau deposition.

They performed both voxel-wise and volume-of-interest (VOI) analyses on the PET data to investigate the associations between mGluR5 binding, tau deposition, and cognitive performance.

Datasets

The study used data from 15 patients with mild Alzheimer's disease and 13 normal controls. No new datasets were introduced.

Key Insights and Ideas

  • mGluR5 and Tau: A Tangled Relationship: The most striking finding is the direct negative correlation between tau deposition and mGluR5 availability in the hippocampus. This suggests that as tau pathology increases in this critical brain region, the availability of mGluR5 receptors decreases.
  • Hippocampal Hub: The hippocampus emerges as a key player, showing both reduced mGluR5 binding and increased tau deposition in mild AD patients compared to controls. This region is vital for memory formation, and its dysfunction is strongly implicated in early cognitive impairment.
  • Cognitive Decline Linked to Receptor and Tangle Load: Lower scores on neuropsychological tests were associated with both reduced mGluR5 availability and increased tau accumulation in the hippocampus. This reinforces the idea that these molecular changes directly impact cognitive function.
  • Potential for Tau Spread: The observed interrelation between mGluR5 and tau in the hippocampus hints at a possible role for mGluR5 in the spread of tau pathology throughout the brain.

Key Results

  • Individuals with mild AD exhibited significantly smaller clusters of [18F] PSS232 binding (indicating lower mGluR5 availability) in the hippocampus compared to controls.
  • Mild AD patients also showed increased tau deposition ([18F] MK6240 binding) in multiple brain regions, including the hippocampus, lateral temporal, posterior cingulate, frontal, occipital, and parietal areas.
  • A significant negative correlation was found between tau deposition and mGluR5 availability in the hippocampus (r = -0.56, p = 0.002).
  • Lower scores on neuropsychological tests were associated with decreased [18F] PSS232 binding and increased [18F] MK6240 binding in the hippocampus.

Limitations and Future Work

The authors acknowledge that this was a cross-sectional study, which limits the ability to establish causality. They emphasize the need for more longitudinal data to fully understand the role of mGluR5 in AD pathology. Future research should also investigate these associations in more severe stages of AD and explore the potential of targeting mGluR5 for therapeutic interventions.

Summary updated

Abstract

Abstract Background Alzheimer's disease (AD) is characterized by the deposition of amyloid plaques and tau neurofibrillary tangles in the brain with continuous cognitive impairment. Although the mechanism underlying AD pathogenesis remains unclear, more evidence suggests that synaptic dysfunction and loss may be an early event in disease progression. Metabotropic glutamate receptor 5 (mGluR5), a kind of G protein–coupled receptor, is involved in AD pathology through modulating synaptic transmission and plasticity and thus exhibits therapeutic effects. However, research on the associations of mGluR5 with the neuropathological hallmarks of AD needs to be completed. Method In this single‐center, cross‐sectional study, fifteen patients with mild AD and thirteen normal controls (CN) underwent a PET/MRI scan with [18F] PSS232 (mGluR5 availability) and trouble PET/CT scan with [18F] florbetapir (β‐amyloid) and [18F] MK6240 (tau deposition). The associations of [18F] PSS232 and [18F] MK6240 binding were investigated. We also investigated the correlations of tau deposition and mGluR5 availability with cognitive performance. Voxel‐wise and volume‐of‐interest (VOI) analyses were performed on PET data. Result Compared to CN, individuals with mild AD showed smaller clusters of [18F] PSS232 binding in the hippocampus and increased tau deposition in the hippocampus, lateral temporal, posterior cingulate, frontal, occipital, and parietal (Figure 1). Based on Voxel‐wise and VOI analyses, tau deposition in the hippocampus was negatively associated with [18F] PSS232 binding in the hippocampus (r = 0.56, p = 0.002, Figure 2). Lower neuropsychological test scores were associated with decreased [18F] PSS232 and increased [18F] MK6240 binding in the hippocampus (Figure 3). Conclusion Patients with mild AD have significant reductions in mGluR5 availability and have high tau deposition in the hippocampus, which is considered the critical region involved in early cognitive impairment. That means mGluR5 and tau were interrelated in the hippocampus and may apply in tau spreading. The correlation of mGluR5 availability and tau deposition in severe AD patients and more longitudinal data are needed to illustrate the role of mGluR5 in AD pathology.
BibTeX
@inproceedings{wang2024metabolic,
  author = {Yan Wang and Fang Xie and Yihui Guan},
  title = {{Metabolic glutamate receptor 5 (mGluR5) is associated with tau pathology in mild Alzheimer's disease}},
  booktitle = {Alzheimer},
  year = {2024},
  doi = {10.1002/alz.089034},
}
Figure